WO2002036614A2 - Peptides destines a une utilisation dans le traitement de la maladie d'alzheimer - Google Patents
Peptides destines a une utilisation dans le traitement de la maladie d'alzheimer Download PDFInfo
- Publication number
- WO2002036614A2 WO2002036614A2 PCT/GB2001/004843 GB0104843W WO0236614A2 WO 2002036614 A2 WO2002036614 A2 WO 2002036614A2 GB 0104843 W GB0104843 W GB 0104843W WO 0236614 A2 WO0236614 A2 WO 0236614A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- protein
- phosphorylated
- binding
- fragment
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 195
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 23
- 238000011282 treatment Methods 0.000 title claims abstract description 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 77
- 238000009739 binding Methods 0.000 claims abstract description 66
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 48
- 101150012716 CDK1 gene Proteins 0.000 claims abstract description 47
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 47
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 47
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 claims abstract description 46
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 14
- 102000001253 Protein Kinase Human genes 0.000 claims abstract description 10
- 108060006633 protein kinase Proteins 0.000 claims abstract description 10
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 5
- 239000012634 fragment Substances 0.000 claims description 45
- 102000016938 Catalase Human genes 0.000 claims description 40
- 108010053835 Catalase Proteins 0.000 claims description 40
- 238000006366 phosphorylation reaction Methods 0.000 claims description 39
- 230000026731 phosphorylation Effects 0.000 claims description 36
- 150000001413 amino acids Chemical group 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 29
- 101001035740 Homo sapiens 3-hydroxyacyl-CoA dehydrogenase type-2 Proteins 0.000 claims description 18
- 238000003556 assay Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 102100039358 3-hydroxyacyl-CoA dehydrogenase type-2 Human genes 0.000 claims description 17
- 108091000080 Phosphotransferase Proteins 0.000 claims description 13
- 102000020233 phosphotransferase Human genes 0.000 claims description 13
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 230000003993 interaction Effects 0.000 claims description 11
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 10
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 102000016736 Cyclin Human genes 0.000 claims description 7
- 108050006400 Cyclin Proteins 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 7
- 229940043355 kinase inhibitor Drugs 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 239000003909 protein kinase inhibitor Substances 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 abstract description 8
- 108090000790 Enzymes Proteins 0.000 abstract description 8
- 230000001472 cytotoxic effect Effects 0.000 abstract description 8
- 231100000433 cytotoxic Toxicity 0.000 abstract description 6
- 230000006970 Aβ cytotoxicity Effects 0.000 abstract description 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 33
- 230000000295 complement effect Effects 0.000 description 19
- 239000000758 substrate Substances 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 15
- 102000008178 Cyclin B1 Human genes 0.000 description 14
- 108010060385 Cyclin B1 Proteins 0.000 description 14
- 230000003013 cytotoxicity Effects 0.000 description 12
- 231100000135 cytotoxicity Toxicity 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000000284 extract Substances 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 108091033380 Coding strand Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 102220471545 Single-stranded DNA cytosine deaminase_S26A_mutation Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229950006137 dexfosfoserine Drugs 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002169 hydrotherapy Methods 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 235000008476 powdered milk Nutrition 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101000715499 Homo sapiens Catalase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 102000045501 human CAT Human genes 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001696 purinergic effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000013391 scatchard analysis Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 230000007351 Aβ plaque formation Effects 0.000 description 1
- 230000006974 Aβ toxicity Effects 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 101000868643 Homo sapiens G2/mitotic-specific cyclin-B1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101800004193 Peptide P3 Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- -1 antibodies Chemical class 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000047813 human CCNB1 Human genes 0.000 description 1
- 102000056838 human CDK1 Human genes 0.000 description 1
- 102000057182 human HSD17B10 Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- ASHGTUMKRVIOLH-UHFFFAOYSA-L potassium;sodium;hydrogen phosphate Chemical compound [Na+].[K+].OP([O-])([O-])=O ASHGTUMKRVIOLH-UHFFFAOYSA-L 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011536 re-plating Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Selon l'invention, des peptides antisens correspondant à des résidus de protéine ß-amyloïde 1-43 sont identifiés, et employés pour l'identification de sites de liaison de protéines sur des enzymes interagissant avec ß-amyloïde. Ces peptides antisens peuvent servir d'agents thérapeutiques, ou à l'identification d'agents thérapeutiques empêchant la cytotoxicité de ß-amyloïde, et éventuellement se révéler utiles dans le traitement de la maladie d'Alzheimer. Lesdits peptides présentent une similarité séquentielle avec la protéine kinase cdc2, la forme cytotoxique de ßA étant phosphorylée.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01980678A EP1363939A2 (fr) | 2000-11-01 | 2001-11-01 | Peptides destines a une utilisation dans le traitement de la maladie d'alzheimer |
| AU2002212471A AU2002212471A1 (en) | 2000-11-01 | 2001-11-01 | Peptides for use in the treatment of alzheimer's disease |
| US10/415,383 US20040072753A1 (en) | 2000-11-01 | 2001-11-01 | Peptides for use in the treatment of alzheimer's disease |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0026739.3 | 2000-11-01 | ||
| GB0026739A GB0026739D0 (en) | 2000-11-01 | 2000-11-01 | Peptides for use in detection and therapeutic targeting of alzheimers disease |
| GB0026738A GB0026738D0 (en) | 2000-11-01 | 2000-11-01 | Diagnosis and therapeutic targeting of alzheimers disease in humans |
| GB0026738.5 | 2000-11-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002036614A2 true WO2002036614A2 (fr) | 2002-05-10 |
| WO2002036614A3 WO2002036614A3 (fr) | 2003-10-02 |
Family
ID=26245223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2001/004843 WO2002036614A2 (fr) | 2000-11-01 | 2001-11-01 | Peptides destines a une utilisation dans le traitement de la maladie d'alzheimer |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20040072753A1 (fr) |
| EP (2) | EP1538163A3 (fr) |
| AU (1) | AU2002212471A1 (fr) |
| WO (1) | WO2002036614A2 (fr) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004058239A1 (fr) * | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Formulations therapeutiques destinees au traitement de maladies liees au peptide beta-amyloide |
| WO2005063796A1 (fr) * | 2003-12-31 | 2005-07-14 | Posco | Inhibiteurs de maturation de proteine precurseur amyloide |
| US7341991B2 (en) | 2003-12-31 | 2008-03-11 | Posco | Inhibitors of amyloid precursor protein processing |
| WO2011113819A3 (fr) * | 2010-03-19 | 2011-11-10 | Immatics Biotechnologies Gmbh | Nouvelle immunothérapie contre plusieurs tumeurs y compris le cancer gastro-intestinal et le cancer gastrique |
| US8318687B2 (en) * | 2003-06-13 | 2012-11-27 | Takeshi Tabira | Recombinant adeno-associated virus vector for treatment of Alzheimer disease |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| AU2015200751B2 (en) * | 2010-03-19 | 2016-11-10 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US9822171B2 (en) | 2010-04-15 | 2017-11-21 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US9951125B2 (en) | 2006-11-30 | 2018-04-24 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
| US10208109B2 (en) | 2005-11-30 | 2019-02-19 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
| US10464976B2 (en) | 2003-01-31 | 2019-11-05 | AbbVie Deutschland GmbH & Co. KG | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
| US10538581B2 (en) | 2005-11-30 | 2020-01-21 | Abbvie Inc. | Anti-Aβ globulomer 4D10 antibodies |
| CN113061161A (zh) * | 2021-04-02 | 2021-07-02 | 河南省农业科学院动物免疫学重点实验室 | 靶向amyloid-beta结构的抑制性肽配基及应用 |
| US11969455B2 (en) | 2010-03-19 | 2024-04-30 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006028429A2 (fr) * | 2002-08-05 | 2006-03-16 | The Johns Hopkins University | Peptide pour cibler l'antigene prostatique membranaire specifique |
| WO2008104386A2 (fr) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Méthode de traitement d'amyloïdoses |
| US20100173828A1 (en) * | 2008-07-25 | 2010-07-08 | Abbott Gmbh & Co. Kg | Aß(X - 38 .. 43) oligomers, and processes, compositions, and uses thereof |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0586790A1 (fr) * | 1992-04-20 | 1994-03-16 | The General Hospital Corporation | Protéine analogue au précurseur de la substance amyloide et ses utilisations |
| WO1994015967A1 (fr) * | 1992-12-31 | 1994-07-21 | Bergmann Johanna E | Agents preventifs et therapeutiques de la maladie de parkinson |
| US5385915A (en) * | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| US5837449A (en) * | 1991-12-24 | 1998-11-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating β-amyloid |
| US5854204A (en) * | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| DE69432629T3 (de) * | 1993-01-25 | 2008-01-17 | Takeda Pharmaceutical Co. Ltd. | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
| US6268479B1 (en) * | 1997-03-12 | 2001-07-31 | The Trustees Of Columbia University In The City Of New York | Intracellular amyloid-beta peptide binding (ERAB) polypeptide |
| US6380370B1 (en) * | 1997-08-14 | 2002-04-30 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US5891719A (en) * | 1997-11-16 | 1999-04-06 | Tularik Inc. | IKAP nucleic acids |
-
2001
- 2001-11-01 EP EP04025899A patent/EP1538163A3/fr not_active Withdrawn
- 2001-11-01 AU AU2002212471A patent/AU2002212471A1/en not_active Abandoned
- 2001-11-01 EP EP01980678A patent/EP1363939A2/fr not_active Withdrawn
- 2001-11-01 US US10/415,383 patent/US20040072753A1/en not_active Abandoned
- 2001-11-01 WO PCT/GB2001/004843 patent/WO2002036614A2/fr not_active Application Discontinuation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385915A (en) * | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| US5837449A (en) * | 1991-12-24 | 1998-11-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating β-amyloid |
| EP0586790A1 (fr) * | 1992-04-20 | 1994-03-16 | The General Hospital Corporation | Protéine analogue au précurseur de la substance amyloide et ses utilisations |
| WO1994015967A1 (fr) * | 1992-12-31 | 1994-07-21 | Bergmann Johanna E | Agents preventifs et therapeutiques de la maladie de parkinson |
| US5854204A (en) * | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
Non-Patent Citations (6)
| Title |
|---|
| DATABASE EMBL [Online] 1 January 1998 (1998-01-01) TAYLOR C B ET AL: "Identification and characterization of genes with unstable transcripts (GUTs) in tobacco" Database accession no. O24158 XP002211379 * |
| IIJIMA K ET AL: "Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5." JOURNAL OF NEUROCHEMISTRY. UNITED STATES SEP 2000, vol. 75, no. 3, September 2000 (2000-09), pages 1085-1091, XP002223098 ISSN: 0022-3042 * |
| MILTON NATHANIEL G N ET AL: "Identification of amyloid-beta binding sites using an antisense peptide approach." NEUROREPORT, vol. 12, no. 11, 2001, pages 2561-2566, XP002211378 ISSN: 0959-4965 cited in the application * |
| SUZUKI T ET AL: "CELL CYCLE-DEPENDENT REGULATION OF THE PHOSPHORYLATION AND METABOLISM OF THE ALZHEIMER AMYLOID PRECURSOR" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 13, no. 5, 1994, pages 1114-1122, XP002942431 ISSN: 0261-4189 * |
| SUZUKI TOSHIHARU ET AL: "Phosphorylation of Alzheimer beta-amyloid precursor-like proteins." BIOCHEMISTRY, vol. 36, no. 15, 1997, pages 4643-4649, XP002223097 ISSN: 0006-2960 * |
| WALTER JOCHEN ET AL: "Ectodomain phosphorylation of beta-amyloid precursor protein at two distinct cellular locations." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 3, 1997, pages 1896-1903, XP002223099 ISSN: 0021-9258 * |
Cited By (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004058239A1 (fr) * | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Formulations therapeutiques destinees au traitement de maladies liees au peptide beta-amyloide |
| US10464976B2 (en) | 2003-01-31 | 2019-11-05 | AbbVie Deutschland GmbH & Co. KG | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
| US8318687B2 (en) * | 2003-06-13 | 2012-11-27 | Takeshi Tabira | Recombinant adeno-associated virus vector for treatment of Alzheimer disease |
| WO2005063796A1 (fr) * | 2003-12-31 | 2005-07-14 | Posco | Inhibiteurs de maturation de proteine precurseur amyloide |
| US7341991B2 (en) | 2003-12-31 | 2008-03-11 | Posco | Inhibitors of amyloid precursor protein processing |
| US10538581B2 (en) | 2005-11-30 | 2020-01-21 | Abbvie Inc. | Anti-Aβ globulomer 4D10 antibodies |
| US10323084B2 (en) | 2005-11-30 | 2019-06-18 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
| US10208109B2 (en) | 2005-11-30 | 2019-02-19 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
| US9951125B2 (en) | 2006-11-30 | 2018-04-24 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
| US10933118B2 (en) | 2010-03-19 | 2021-03-02 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| AU2011229199B2 (en) * | 2010-03-19 | 2015-01-22 | Immatics Biotechnologies Gmbh | Novel Immunotherapy Against Several Tumors Including Gastrointestinal and Gastric Cancer |
| US11969455B2 (en) | 2010-03-19 | 2024-04-30 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US9101585B2 (en) | 2010-03-19 | 2015-08-11 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| CN102905721B (zh) * | 2010-03-19 | 2015-09-23 | 伊玛提克斯生物技术有限公司 | 包括胃肠癌和胃癌的几种肿瘤的新型免疫疗法 |
| CN105001339A (zh) * | 2010-03-19 | 2015-10-28 | 伊玛提克斯生物技术有限公司 | 包括胃肠癌和胃癌的几种肿瘤的新型免疫疗法 |
| KR101656913B1 (ko) * | 2010-03-19 | 2016-09-13 | 이매틱스 바이오테크놀로지스 게엠베하 | 위장암 및 위암을 비롯한 여러가지 종양에 대한 신규한 면역 요법 |
| EA024497B1 (ru) * | 2010-03-19 | 2016-09-30 | Имматикс Байотекнолоджиз Гмбх | Пептид, связывающийся с молекулой главного комплекса гистосовместимости человека i класса, и его применение для лечения рака |
| AU2015200751B2 (en) * | 2010-03-19 | 2016-11-10 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US9717774B2 (en) | 2010-03-19 | 2017-08-01 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| TWI486445B (zh) * | 2010-03-19 | 2015-06-01 | Immatics Biotechnologies Gmbh | 包括胃腸癌和胃癌的幾種腫瘤的新型免疫療法 |
| US9895415B2 (en) | 2010-03-19 | 2018-02-20 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| EP2845604A3 (fr) * | 2010-03-19 | 2015-05-20 | immatics biotechnologies GmbH | Nouvelle immunothérapie contre plusieurs tumeurs, y compris le cancer gastrique et gastro-intestinal |
| AU2017200376B2 (en) * | 2010-03-19 | 2018-04-26 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US9993523B2 (en) | 2010-03-19 | 2018-06-12 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US11957730B2 (en) | 2010-03-19 | 2024-04-16 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US10064913B2 (en) | 2010-03-19 | 2018-09-04 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US11839643B2 (en) | 2010-03-19 | 2023-12-12 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| JP2013521789A (ja) * | 2010-03-19 | 2013-06-13 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 消化管癌および胃癌を含む数種の腫瘍に対する新規免疫療法 |
| US10357540B2 (en) | 2010-03-19 | 2019-07-23 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US10420816B1 (en) | 2010-03-19 | 2019-09-24 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| KR20130016304A (ko) * | 2010-03-19 | 2013-02-14 | 이매틱스 바이오테크놀로지스 게엠베하 | 위장암 및 위암을 비롯한 여러가지 종양에 대한 신규한 면역 요법 |
| US10478471B2 (en) | 2010-03-19 | 2019-11-19 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| CN102905721A (zh) * | 2010-03-19 | 2013-01-30 | 伊玛提克斯生物技术有限公司 | 基于avl9的癌症的诊断及治疗 |
| CN105001339B (zh) * | 2010-03-19 | 2020-10-16 | 伊玛提克斯生物技术有限公司 | 包括胃肠癌和胃癌的几种肿瘤的新型免疫疗法 |
| US10898546B2 (en) | 2010-03-19 | 2021-01-26 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US10905741B2 (en) | 2010-03-19 | 2021-02-02 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| WO2011113819A3 (fr) * | 2010-03-19 | 2011-11-10 | Immatics Biotechnologies Gmbh | Nouvelle immunothérapie contre plusieurs tumeurs y compris le cancer gastro-intestinal et le cancer gastrique |
| US11883462B2 (en) | 2010-03-19 | 2024-01-30 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US11077171B2 (en) | 2010-03-19 | 2021-08-03 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US11273200B2 (en) | 2010-03-19 | 2022-03-15 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US11298404B2 (en) | 2010-03-19 | 2022-04-12 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US11648292B2 (en) | 2010-03-19 | 2023-05-16 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US11850274B2 (en) | 2010-03-19 | 2023-12-26 | Immatics Biotechnologies Gmbh | Immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US9822171B2 (en) | 2010-04-15 | 2017-11-21 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US10047121B2 (en) | 2010-08-14 | 2018-08-14 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| CN113061161B (zh) * | 2021-04-02 | 2023-09-12 | 河南省农业科学院动物免疫学重点实验室 | 靶向amyloid-beta结构的抑制性肽配基及应用 |
| CN113061161A (zh) * | 2021-04-02 | 2021-07-02 | 河南省农业科学院动物免疫学重点实验室 | 靶向amyloid-beta结构的抑制性肽配基及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002212471A1 (en) | 2002-05-15 |
| EP1538163A2 (fr) | 2005-06-08 |
| EP1363939A2 (fr) | 2003-11-26 |
| US20040072753A1 (en) | 2004-04-15 |
| EP1538163A3 (fr) | 2005-06-15 |
| WO2002036614A3 (fr) | 2003-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1538163A2 (fr) | Protéine Beta-Amyloide 1-43 Phosphorylée et son Utilisation pour le Traitment de la Maladie d'Alzheimer | |
| Shetty et al. | cdc2-like kinase from rat spinal cord specifically phosphorylates KSPXK motifs in neurofilament proteins: isolation and characterization. | |
| Schubert et al. | Amyloid β protein precursor is possibly a heparan sulfate proteoglycan core protein | |
| Walsh et al. | The inhibitor protein of the cAMP-dependent protein kinase | |
| Weng et al. | Identification of Src, Fyn, and Lyn SH3-binding proteins: implications for a function of SH3 domains | |
| US20080107673A1 (en) | Mutants of clostridium difficile toxin B and methods of use | |
| WO1998022120A1 (fr) | Reactifs pour traiter et diagnostiquer la maladie d'alzheimer | |
| JP2000032983A (ja) | アルツハイマ―病の診断および治療用の新規な手段 | |
| US6280964B1 (en) | Binding sites for phosphotyrosine binding domains | |
| Seigneur et al. | A lysine‐and glutamic acid‐rich protein, KERP1, from Entamoeba histolytica binds to human enterocytes | |
| US5260200A (en) | Isolated DNA encoding an insulin receptor substrate | |
| JPH10510422A (ja) | チロシンリン酸化タンパク質に結合する新規なタンパク質ドメイン | |
| Jones et al. | The C‐terminal region of the major outer sheath protein of Treponema denticola inhibits neutrophil chemotaxis | |
| CN107921084B (zh) | 含有活动精子结构域的蛋白质2和炎症 | |
| PL201887B1 (pl) | Peptyd, polinukleotyd kodujący ten peptyd, szczepionka, zastosowanie peptydu i polinukleotydu kodującego ten peptyd oraz przeciwciało | |
| HUT77081A (hu) | Protein kináz NPK-110 | |
| US7364870B2 (en) | MK2 interacting proteins | |
| EP2388012A1 (fr) | Peptides de Kisspeptine pour le traitement de la maladie d'Alzheimer, la maladie de Creutzfeldt-Jakob ou de diabète | |
| JP2001510684A (ja) | アッセイ、治療法及び治療手段 | |
| KR102111030B1 (ko) | Jab1을 포함하는 신경세포 분화 탐지용 바이오마커 또는 신경세포 분화 촉진용 조성물 | |
| WO2015022549A1 (fr) | Composés de liaison à la map kinase p38 | |
| JP3471879B2 (ja) | セリンキナーゼ活性の抑制方法、ｐｉ３−キナーゼのサブユニット間の結合活性の調整方法、ｐｉ３−キナーゼのサブユニット結合抗体、この抗体を生成するハイブリドーマ細胞系、核酸分子、プラスミド、アゴニスト、アンタゴニスト、ｐｉ３−キナーゼ活性を抑制するサブユニット結合分子、サブユニットの存在検出方法、ｐｉ３−キナーゼ活性の抑制剤製造方法、およびｐｉ３−キナーゼ活性の抑制剤 | |
| JPH02311498A (ja) | 機能性ポリペプチド | |
| JP5939528B2 (ja) | カルモジュリン様皮膚タンパク質を有効成分として含む医薬組成物 | |
| US20070134752A1 (en) | Smooth muscle myosin phosphatase associated kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2001980678 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10415383 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 2001980678 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2001980678 Country of ref document: EP |